You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Netupitant; palonosetron hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for netupitant; palonosetron hydrochloride and what is the scope of freedom to operate?

Netupitant; palonosetron hydrochloride is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Netupitant; palonosetron hydrochloride has seventy-six patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for netupitant; palonosetron hydrochloride
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for netupitant; palonosetron hydrochloride
Generic Entry Date for netupitant; palonosetron hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for netupitant; palonosetron hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Helsinn Healthcare SAPhase 4
Instituto Brasileiro de Controle do CancerPhase 2
Albert Einstein College of Medicine, Inc.Phase 2

See all netupitant; palonosetron hydrochloride clinical trials

US Patents and Regulatory Information for netupitant; palonosetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for netupitant; palonosetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 ⤷  Try a Trial ⤷  Try a Trial
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for netupitant; palonosetron hydrochloride

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2011061622 ⤷  Try a Trial
China 106421793 用于治疗中枢介导的恶心及呕吐的组合物及方法 (COMPOSITIONS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING) ⤷  Try a Trial
Poland 2722045 ⤷  Try a Trial
Chile 2012001276 Capsula o tableta que comprende 0,25-0,75 mg de palonosetron y 200-400 mg de netupitant, o sales de ellos; forma de dosificacion en capsula que comprende: una cubierta externa, tabletas que comprenden netupitant o una sal y capsulas que comprenden palonosetron o una sal; util en el tratamiento de nausea y vomito. ⤷  Try a Trial
Ukraine 105817 КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ТОШНОТЫ И РВОТЫ ЦЕНТРАЛЬНОГО ПРОИСХОЖДЕНИЯ;КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ НУДОТИ І БЛЮВАННЯ ЦЕНТРАЛЬНОГО ПОХОДЖЕННЯ (Normal;heading 1;heading 2;heading 3;COMPOSITIONS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING) ⤷  Try a Trial
New Zealand 599439 Compositions and methods for treating centrally mediated nausea and vomiting ⤷  Try a Trial
China 104856998 Compositions for treating centrally mediated nausea and vomiting ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for netupitant; palonosetron hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2785706 122020000050 Germany ⤷  Try a Trial PRODUCT NAME: FOSNETUPITANT; REGISTRATION NO/DATE: C(2020)1804(FINAL) 20200316
1035115 CR 2015 00044 Denmark ⤷  Try a Trial PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
1035115 1590040-0 Sweden ⤷  Try a Trial PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
1035115 C01035115/01 Switzerland ⤷  Try a Trial PRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015
2785706 C20200029 00371 Estonia ⤷  Try a Trial PRODUCT NAME: FOSNETUPITANT;REG NO/DATE: EU/1/15/1001; 18.03.2020
2785706 2090015-5 Sweden ⤷  Try a Trial PRODUCT NAME: FOSNETUPITANT; REG. NO/DATE: EU/1/15/1001 20200317
1035115 43/2015 Austria ⤷  Try a Trial PRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: EU/1/15/1001 20150527
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.